Can we prevent Parkinson's disease with n-3 polyunsaturated fatty acids?

Future Lipidology

Volumn 3, Issue 2, 2008, Pages 133-137

  Calon, Frédéric ^a,b   Cicchetti, Francesca ^a,b  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

Author keywords

Docosahexaenoic acid; Eicosapentaenoic acid; Environmental risk factors; MPTP; Neuroprotection; Nutraceuticals; Omega 3; Parkinson; Polyunsaturated fatty acid

Indexed keywords

ALPHA SYNUCLEIN; CACAO EXTRACT; CARBAMIC ACID DERIVATIVE; DOCOSAHEXAENOIC ACID; ICOSAPENTAENOIC ACID; LEUCINE RICH REPEAT KINASE 2; MANEB; OMEGA 3 FATTY ACID; ORGANOPHOSPHATE PESTICIDE; PARAQUAT; PARKIN; PESTICIDE; PLANT EXTRACT; RED CLOVER EXTRACT; S METHYLCYSTEINE; TANGERINE EXTRACT;

ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CACAO; CLINICAL TRIAL; DIET SUPPLEMENTATION; DRUG EFFICACY; DRUG SAFETY; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL FACTOR; FAT INTAKE; FISH; FOOD INTAKE; GENE MUTATION; GENETIC PREDISPOSITION; HUMAN; INCIDENCE; MOOD DISORDER; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PREVALENCE; PRIMARY PREVENTION; PRIORITY JOURNAL; RISK FACTOR; RISK REDUCTION; TANGERINE;

ANIMALIA;

EID: 47249137372     PISSN: 17460875     EISSN: None     Source Type: Journal    
DOI: 10.2217/17460875.3.2.133     Document Type: Article

References (72)

1. Aminoff MJ: Parkinson's disease and other extrapyramidal disorders. In: Harrison's Principles of Internal Medicine. Kasper DL, Braunwald E, Fauci AS et al. (Eds). McGraw-Hill Professional, NY, USA 2399-2406 (2004).
2. Brice A: Genetics of Parkinson's disease: LRRK2 on the rise. Brain 128(Pt 12), 2760-2762 (2005).
3. Gasser T: Genetics of Parkinson's disease. Curr. Opin. Neurol. 18(4), 363-369 (2005).
4. Feany MB: New genetic insights into Parkinson's disease. N. Engl J. Med. 351(19), 1937-1940 (2004).
5. Farrer MJ: Genetics of Parkinson disease: paradigm shifts and future prospects. Nat. Rev. Genet. 7(4), 306-318 (2006).
6. Tanner CM, Ottman F, Goldman SM et al.: Parkinson disease in twins: an etiologic study. JAMA 281(4), 341-346 (1999).
7. Schapira AH: Disease modification in Parkinson's disease. Lancet Neurol. 3(6), 362-368 (2004).
8. Moore DJ, West AB, Dawson VL, Dawson TM: Molecular pathophysiology of Parkinson's disease. Annu. Rev. Neurosci. 28, 57-87 (2005).
9. Beal MF: Experimental models of Parkinson's disease. Nat. Rev. Neurosci. 2, 325-334 (2001).
10. Betarbet R, Sherer TB, Greenamyre JT: Animal models of Parkinson's disease. Bioessays 24, 308-318 (2002).
11. Dawson T, Mandir A, Lee M: Animal models of Parkinson's disease: pieces of the same puzzle? Neuron 35, 219-222 (2002).
12. Di Monte DA, Lavasani M, Manning-Bog AB: Environmental factors in Parkinson's disease. Neurotoxicology 23, 487-502 (2002).
13. Landrigan PJ, Sonawane B, Butler RN, Trasande L, Callan R, Droller D: Early environmental origins of neurodegenerative disease in later life. Environ. Health Perspect. 113(9), 1230-1233 (2005).
14. Ascherio A, Chen H, Veisskopf MG et al.: Pesticide exposure and risk for Parkinson's disease. Ann. Neurol. 60(2), 197-203 (2006).
15. Dick FD: Parkinson's disease and pesticide exposures. Br. Med. Bull. 79-80, 219-231 (2006).
16. Dinis-Oliveira RJ, Remiao F, Carmo H et al.: Paraquat exposure as an etiological factor of Parkinson's disease. Neurotoxicology 27(6), 1110-1122 (2006).
17. Peng J, Peng L, Stevenson FF, Doctrow SF, Andersen JK: Iron and paraquat as synergistic environmental risk factors in sporadic Parkinson's disease accelerate age-related neurodegeneration. J. Neurosci. 27(26), 6914-6922 (2007).
18. Cicchetti F, Lapointe N, Roberge-Tremblay A et al.: Systemic exposure to paraquat and maneb models early Parkinson's disease in young adult rats. Neurobiol. Dis. 20(2), 360-371 (2005).
19. Chaturvedi S, Ostbye T, Stoessl AJ, Merskey H, Hachinski V: Environmental exposures in elderly Canadians with Parkinson's disease. Can. J. Neurol. Sci. 22, 232-234 (1995).
20. Corasaniti MT, Strongoli MC, Rotiroti D, Bagetta G, Nistico G: Paraquat: a useful tool for the in vivo study of mechanisms of neuronal cell death. Pharmacol. Toxicol. 83(1), 1-7 (1998).
21. Chen H, O'Reilly E, McCullough ML et al.: Consumption of dairy products and risk of Parkinson's disease. Am. J. Epidemiol. 165(9), 998-1006 (2007).
22. de Lau LM, Koudstaal PJ, Witteman JC, Hofman A, Breteler MM: Dietary folate, vitamin B12, and vitamin B6 and the risk of Parkinson disease. Neurology 67(2), 315-318 (2006).
23. Hu G, Bidel S, Jousilahti P, Antikainen R, Tuomilehto J: Coffee and tea consumption and the risk of Parkinson's disease. Mov. Disord. 22(15), 2242-2248 (2007).
24. Datla KP, Zbarsky V, Rai D et al.: Short-term supplementation with plant extracts rich in flavonoids protect nigrostriatal dopaminergic neurons in a rat model of Parkinson's disease. J. Am. Coll. Nutr. 26(4), 341-349 (2007).
25. Wassef R, Haenold R, Hansel A, Brot N, Heinemann SH, Hoshi T: Methionine sulfoxide reductase A and a dietary supplement S-methyl-L-cysteine prevent Parkinson's-tike symptoms. J. Neurosci. 27(47), 12808-12816 (2007).
26. Salem N Jr, Litman B, Kim HY, Gawrisch K: Mechanisms of action of docosahexaenoic acid in the nervous system. Lipids 36(9), 945-959 (2001).
27. Julien C, Berthiaume L, Hadj-Tahar A et al.: Postmortem brain fatty acid profile of levodopa-treated Parkinson disease patients and parkinsonian monkeys. Neurochem Int. 48(5), 404-414 (2006).
28. Calon F, Lim GP, Yang F et al.: Docosahexaenoic acid protects from dendritic pathology in an Alzheimer's disease mouse model. Neuron 43(5), 633-645 (2004).
29. Calon F, Lim GP, Morihara T et al.: Dietary n-3 polyunsaturated fatty acid depletion activates caspases and decreases NMDA receptors in the brain of a transgenic mouse model of Alzheimei's disease. Eur. J. Neurosci. 22(3), 617-626 (2005).
30. Lim GP Calon F, Morihara T et al.: A diet enriched with the omega-3 &try acid docosahexaenoic acid reduces amyloid burden in an aged Alzheimer mouse model, J. Neurosci. 25 (12), 3032-3040 (2005).
31. Oksman M, Iivonen H, Hogyes E et al.: Impact of different saturated fatty acid, polyunsaturated fatty acid and cholesterol containing diets on β-amyloid accumulation in APP/PS1 transgenic mice. Neurobiol Dis. 23(3), 563-572 (2006).
32. Green KN, Martinez-Coria H, Khashwji H et al.: Dietary docosahexaenoic acid and docosapentaenoic acid ameliorate amyloid-β and tau pathology via a mechanism involving presenilin 1 levels. J. Neurosci. 27(16), 4385-4395 (2007).
33. Hashimoto M, Hossain S, Shimada T et al.: Docosahexaenoic acid provides protection from impairment of learning ability in Alzheimer's disease model rats. J. Neurochem. 81(5), 1084-1191 (2002).
34. Bazan NG: Neuroprotectin D1 (NPD1): a DHA-derived mediator that protects brain and retina against cell injury-induced oxidative stress. Brain Pathol. 15(2), 159-166 (2005).
35. Jump DB: The biochemistry of n-3 polyunsaturated fatty adds. J. Biol. Chem. 277(11), 8755-8878 (2002).
36. Kim HY: Novel metabolism of docosahexaenoic acid in neural cells. J. Biol. Chem. 282(26), 18661-18665 (2007).
37. Hunot S, Hirsch EC: Neuroinflammatory processes in Parkinson's disease. Ann. Neurol. 53(Suppl. 3), S49-S58; discussion S58-S60 (2003).
38. Jenner P: Oxidative stress in Parkinson's disease. Ann. Neurol. 53(Suppl. 3), S26-S36; discussion S36-S38 (2003).
39. Anderson C, Checkoway H, Franklin GM, Beresford S, Smith-Weller T, Swanson PD: Dietary factors in Parkinson's disease: the role of food groups and specific foods. Mov. Disord. 14(1), 21-27 (1999).
40. Logroscino, G, Marder K, Graziano J et al.: Dietary iron, animal fats, and risk of Parkinson's disease. Mov. Disord. 13(Suppl. 1), 13-16 (1998).
41. Logroscino G, Marder K, Cote L, Tang MX, Shea S, Mayeux R. Dietary lipids and antioxidants in Parkinson's disease: a population-based, case-control study. Ann. Neurol. 39(1), 89-94 (1996).
42. Johnson CC, Gorell JM, Rybicki BA, Sanders K, Peterson EL: Adult nutrient intake as a risk factor for Parkinson's disease. Int. J. Epidemiol. 28(6), 1102-1109 (1999).
43. Abbott RD, Ross GW, White LR et al.: Environmental, life-style, and physical precursors of clinical Parkinson's disease: recent findings from the Honolulu-Asia Aging Study. J. Neurol. 250(Suppl. 3), III30-III39 (2003).
44. Hellenbrand W, Seidler A, Boeing H et al.: Diet and Parkinson's disease. 1: a possible role for the past intake of specific foods and food groups. Results from a self-administered food-frequency questionnaire in a case-control study. Neurology 47(3), 636-643 (1996).
45. Morens DM, Grandinetti A, Waslien CI, Park CB, Ross GW, White LR: Case-control study of idiopathic Parkinson's disease and dietary vitamin E intake. Neurology 46(5), 1270-1274 (1996).
46. de Lau LM, Bornebroek M, Witteman JC, Hofman A, Koudstaal PJ, Breteler MM: Dietary fatty acids and the risk of Parkinson disease: the Rotterdam study. Neurology 64(12), 2040-2045 (2005).
47. Chen H, Zhang SM, Hernan MA, Willett WC, Ascherio A: Dietary intakes of fat and risk of Parkinson's disease. Am. J. Epidemiol. 157(11), 1007-1014 (2003).
48. Gao X, Chen H, Fung TT et al.: Prospective study of dietary pattern and risk of Parkinson disease. Am. J. Clin. Nutr. 86(5), 1486-1494 (2007).
49. Bezard E: A call for clinically driven experimental design in assessing neuroprotection in experimental Parkinsonism. Behav. Pharmacol. 17(5-6), 379-382 (2006).
50. Hirsch EC: How to judge animal models of Parkinson's disease in terms of neuroprotection. J. Neural Transm. Suppl. 70, 255-260 (2006).
51. Dauer W, Przedborski S: Parkinson's disease: mechanisms and models. Neuron 39(6), 889-909 (2003).
52. Tremblay ME, Saint-Pierre M, Bourhis E, Levesque D, Rouillard C, Cicchetti F: Neuroprotective effects of cystamine in aged parkinsonian mice. Neurobiol. Aging 27(6), 862-870 (2006).
53. Jackson-Lewis V, Przedborski S: Protocol for the MPTP mouse model of Parkinson's disease. Nat. Protoc. 2(1), 141-151 (2007).
54. Bousquet M, Saint-Pierre M, Julien C, Salem NJ, Cicchetti F, Caton F: Beneficial effects of dietary omega-3 polyunsaturated fatty acid on toxin-induced neuronal degeneration in an animal model of Parkinson's disease. FASEB J. doi: 10.1096/fj.07-9677com (2007) (Epub ahead of print).
55. Rapoport SI, Rao JS, Igarashi M: Brain metabolism of nutritionally essential polyunsaturated fatty acids depends on both the diet and the liver. Prostaglandins Leukot. Essent. Fatty Acids 77(5-6), 251-261 (2007).
56. Lin YH, Salem NJ: Whole body distribution of deuterated linoleic and α-linolenic acids and their metabolites in the rat. J. Lipid Res. 48(12), 2709-2724 (2007).
57. Igarashi M, DeMar JCJ, Ma K, Chang L, Bell JM, Rapoport SI: Docosahexaenoic acid synthesis from a-linolenic acid by rat brain is unaffected by dietary n-3 PUFA deprivation. J. Lipid Res. 48(5), 1150-1158 (2007).
58. Salem N Jr: Omega-3 fatty acids: molecular and biochemical aspects. In: New Protective Roles for Selected Nutrients. Spiller GA, Scala J (Eds). Wiley-Liss, NY, USA 109-228 (1989).
59. Rapoport SI: In vivo approaches to quantifying and imaging brain arachidonic and docosahexaenoic acid metabolism. J. Pediatr. 143(4 Suppl.), S26-S34 (2003).
60. Demar JC Jr, Ma K, Bell JM, Rapoport SI: Half-lives of docosahexaenoic acid in rat brain phospholipids are prolonged by 15 weeks of nutritional deprivation of n-3 polyunsaturated fatty acids. J. Neurochem. 91(5), 1125-1137 (2004).
61. Alessandri JM, Guesnet P, Vancassel S et al.: Polyunsaturated fatty acids in the central nervous system: evolution of concepts and nutritional implications throughout life. Reprod. Nutr. Dev. 44(6), 509-538 (2004).
62. Roberts LJ, Fessel JP, Davies SS: The biochemistry of the isoprostane, neuroprostane, and isofuran pathways of lipid peroxidation. Brain Pathol. 15(2), 143-148 (2005).
63. Nourooz-Zadeh J, Halliwell B, Anggard EE: Evidence for the formation of F3-isoprostanes during peroxidation of eicosapentaenoic acid. Biocbem. Biophys. Res. Commun. 236(2), 467-472 (1997).
64. Lynch AM, Loane DJ, Minogue AM et al.: Eicosapentaenoic acid confers neuroprotection in the amyloid-β challenged aged hippocampus. Neurobiol. Aging 28(6), 845-855 (2007).
65. Mukherjee PK, Chawla A, Loayza MS, Bazan NG: Docosanoids are multifunctional regulators of neural cell integrity and fate: significance in aging and disease. Prostaglandins Leukot. Essent. Fatty Acids 77(5-6), 233-238 (2007).
66. Gronn M, Christensen E, Hagve TA, Christophersen BO: Peroxisomal retroconversion of docosahexaenoic acid (22:6(n-3)) to eicosapentaenoic acid (20:5(n-3)) studied in isolated rat liver cells. Biochim. Biophys. Acta 1081(1), 85-91 (1991).
67. 13C]22:6n-3-triacylglycerols. Am. J. Clin. Nutr. 64(4), 577-586 (1996).
68. Stahl LA, Begg DP, Weisinger RS, Sinclair AJ: The role of omega-3 fatty acids in mood disorders. Curr. Opin Investig. Drugs 9(1), 57-64 (2008).
69. Ravina BM, Fagan SC, Hart RG et al.: Neuroprotective agents for clinical trials in Parkinson's disease: a systematic assessment. Neurology 60(8), 1234-1240 (2003).
70. Olanow CW, Jankovic J: Neuroprotective therapy in Parkinson's disease and motor complications: a search for a pathogenesis-targeted, disease-modifying strategy. Mov. Disord. 20(Suppl. 11), S3-S10 (2005).
71. Calon F, Cole G: Neuroprotective action of omega-3 polyunsaturated fatty acids against neurodegenerative diseases: evidence from animal studies. Prostaglandins Leukot. Essent. Fatty Acids 77(5-6), 287-293 (2007).
72. Calon F: Nonpatentable drugs and the cost of our ignorance, Canadian Med. Association J. 174(4), 483-484 (2006).